12:00 AM
 | 
Jul 16, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Subcutaneous Orencia abatacept regulatory update

Bristol-Myers submitted a regulatory application to Japan's Ministry of Health, Labor and Welfare (MHLW) for subcutaneous Orencia abatacept to treat rheumatoid arthritis in patients with an inadequate response...

Read the full 119 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >